🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Nasopharyngeal Cancer Recurrent

Clinical Study on the EBV CAR-T /TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma NCT05587543EARLY Phase 11 site📍 Shanghai Fudan University · Tests: PK Blood Collection, CAR, TCR EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma NCT06802835Phase 1, Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: EGFR Antibody, PD-1 antibody, Gemcitabine, Cisplatin, IMRT Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC NCT06657690Phase 21 site📍 Zhuhai Sun Yat-sen University · Tests: Irinotecan liposome, S-1 A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma NCT06976190Phase 31 site📍 Guangzhou Lepu Biopharma Co., Ltd. · Tests: MRG003 + Pucotenlimab, Gemcitabine, Docetaxel, or Capecitabine MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC NCT07331428Phase 21 site📍 Fuzhou Fujian Cancer Hospital · Tests: MRG003, Tislelizumab, Capecitabine Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma NCT04778956Phase 37 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, salvage surgery TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer NCT06868433Phase 12 sites📍 Atlanta📍 Atlanta Emory University · Tests: Autologous Tumor Membrane Vesicles Vaccine, Biospecimen Collection, Computed Tomography, Echocardiography, Magnetic Res… Investigation of Multi-omics Technique to Predict the Efficacy of Chemoradiotherapy Combined With Immunotherapy for r/m NPC NCT06197776n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: cisplatin-based chemoradiotherapy combined with immunotherapy Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer NCT07667400Phase 1, Phase 21 site📍 Bethesda National Cancer Institute (NCI) · Tests: SX-682, DTX Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma. NCT07781358Phase 21 site📍 Shanghai Hongmeng Yu · Tests: Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) NCT06241599Phase 2, Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: GP/PFLL+AK104, GP/PFLL+placebo SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma NCT06323239Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: SBRT, Low-dose Radiotherapy (LDRT), Toripalimab, Gemcitabine, Cisplatin TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma NCT06912711Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Toripalimab, Nimotuzumab, surgery Deep Learning-based sbORN Diagnostic Model NCT06463392n/a1 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: No Intervention: Observational Cohort JS207 a Bispecific Antibody Against PD1-VEGF in Nasopharyngeal Carcinoma NCT07690787Phase 21 site📍 Hong Kong Chinese University of Hong Kong · Tests: JS207, Paclitaxel, Capecitabine Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants NCT00898638n/a4 sites📍 Nashville📍 Nashville📍 Nashville Vanderbilt University Medical Center · Tests: biologic sample preservation procedure, medical chart review Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma NCT04453813Phase 36 sites📍 Guangzhou📍 Guangzhou📍 Shaoguan Sun Yat-sen University · Tests: Toripalimab plus concurrent chemo-radiotherapy, Concurrent chemo-radiotherapy Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors NCT07625423Phase 11 site📍 Chengdu West China Hospital · Tests: EDS01 1.0×10^11 VP + Toripalimab, EDS01 5.0×10^11 VP + Toripalimab, EDS01 1.0×10^12 VP + Toripalimab Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial NCT05340491Phase 312 sites📍 Guangzhou📍 Beijing📍 Chengdu Sun Yat-sen University · Tests: Toripalimab, Chemotherapy, Intensity modulated radiotherapy Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients" NCT01365169NA1 site📍 Houston M.D. Anderson Cancer Center · Tests: Exercise Intervention, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring, Health Telemonitoring Clinical Trial of SIBP-03 in Patients With Head and Neck Squamous Cell Carcinoma NCT06194656Phase 22 sites📍 Shanghai📍 Shanghai Shanghai Institute Of Biological Products · Tests: HER3 Monoclonal antibodies-Dose A, HER3 Monoclonal antibodies-Dose B, HER3 Monoclonal antibodies-Dose C, HER3 Monoclona… Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC NCT06472713Phase 21 site📍 Zhuhai Ming-Yuan Chen · Tests: Mitoxantrone hydrochloride liposome injection, PD-1 Inhibitors Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC NCT06235203Phase 37 sites📍 Shanghai📍 Fuzhou📍 Nanning Eye & ENT Hospital of Fudan University · Tests: endoscopic surgery, Neoadjuvant therapy,Toripalimab Injection and Gemcitabine based therapy, Adjuvant therapy in experi… PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Selective Re-irradiation for Locally Advanced Recurrent NPC NCT07332247Phase 21 site📍 Guangzhou Sun Yat-sen University · Tests: Selective re-irradiation, Immediate re-irradiation SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy NCT06676722Phase 22 sites📍 Xiamen📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: SBRT combined with Nimotuzumab followed by Tislelizumab Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer NCT06980038Phase 212 sites📍 Irvine📍 Los Angeles📍 Los Angeles National Cancer Institute (NCI) · Tests: Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection, Cemiplimab, Computed Tomograp… Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial NCT07070479Phase 26 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Ming-Yuan Chen · Tests: Ivonescimab, Nimotuzumab, Irinotecan liposome, S-1, Mitoxantrone Hydrochloride Liposome Adjuvant vs Surgery Only in Early-stage Recurrent NPC NCT06228079Phase 37 sites📍 Shanghai📍 Fuzhou📍 Nanning Eye & ENT Hospital of Fudan University · Tests: Immunotherapy,Toripalimab Injection, Chemotherapy,Gemcitabine based regimen Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma NCT04136886Phase 31 site📍 Guangzhou Sun Yat-sen University · Tests: Cisplatin, IMRT
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy